ReEngage Therapeutics

Based in the US, ReEngage Therapeutics focuses on developing innovative biopharmaceutical products that target longevity-related diseases through epigenetic modifications. ReEngage Therapeutics specializes in creating biopharmaceutical products aimed at addressing longevity-related diseases. Founded in 2024 in Houston, US, the company has successfully completed 1 deal. Its most recent funding round occurred on August 6, 2025, raising USD 365,000.

The firm has not undergone any significant pivots in its strategy or operations and does not have any known subsidiaries. The founder's history is not available. ReEngage Therapeutics is primarily focused on the development of biopharmaceutical products targeting longevity-related diseases through the modification of epigenetic mechanisms. The company’s core offerings revolve around ACSS2 inhibitors, which are designed to combat aging-related disorders such as neurodegeneration and cancer.

These inhibitors are developed in collaboration with renowned institutions, including a sponsorship agreement with MD Anderson Cancer Center and high-throughput screening partnerships with Scripps Florida. ReEngage Therapeutics aims to address significant unmet medical needs in both the oncology and neurodegenerative disease sectors. While specific geographical markets for these products are not detailed, the company engages with a global clientele comprising healthcare providers, research institutions, and pharmaceutical partners interested in innovative cancer therapies. ReEngage Therapeutics generates revenue through strategic partnerships and research agreements rather than direct sales of products to consumers.

The company’s revenue model primarily hinges on collaborations with academic and clinical institutions, which may involve funded research agreements and exclusive licensing deals for their ACSS2 inhibitor compounds. These transactions often encompass milestone payments based on research progress, as well as potential royalties from future product sales. Given the focus on B2B transactions, ReEngage’s client base likely includes pharmaceutical companies and research organizations engaged in drug development for cancer therapies. Specific pricing structures for its products and services are not disclosed, focusing instead on collaborative agreements that facilitate research and development in the biopharmaceutical space.

In August 2025, ReEngage Therapeutics raised USD 365,000 in venture funding, which will be used to manufacture clinical supplies and coordinate with the FDA on the design of its Phase 1b trial for MTB-9655 in metastatic colorectal cancer. The company is also focused on launching new products designed to address various longevity-related diseases, with specific release dates to be determined. ReEngage is exploring opportunities to expand into new geographic markets, although specific regions have not been disclosed.